Based in New Jersey, Becton, Dickinson and Company BDX is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter fiscal 2015 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $1.94 per share beat the Zacks Consensus Estimate of $1.90. Earnings also increased 11.5% on a year-over-year basis.
Revenues: Adjusted revenues amounted to $3.07 billion, up 39.3% from the prior-year quarter which beat the Zacks Consensus Estimate of $3.06 billion.
Key Stats: BD Lifesciences generated revenues of $976 million, down 3.3% from the year-ago quarter. BD Medical generated revenues of $2.09 billion, up 75.3%.
Major Factors: Becton, Dickinson announced full-year guidance for fiscal 2016. Adjusted earnings per share are expected in the band of $8.37-$8.44. Adjusted revenues for the fiscal year (including accretion from CareFusion acquisition and the impact of foreign currency) are expected to exhibit a growth rate of 23%-25%.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment